ABSTRACT
Introduction In 2021, a joint ESGO/ESTRO/ESP committee updated their evidence-based guidelines for endometrial cancer, recommending a new risk grouping incorporating both clinicopathologic and molecular parameters. We applied the new risk grouping and compared the results to those of the prior 2016 clinicopathologic system.
Materials and methods We classified molecularly a cohort of 604 women diagnosed with endometrial cancer using immunohistochemistry for TP53 and MMR proteins on a tissue microarray, as well as Sanger sequencing for POLE mutations. These results, combined with clinicopathologic data, allowed the patients to be risk grouped using both the new 2021 molecular/clinicopathologic parameters and the prior 2016 clinicopathologic system. In addition, clinical treatment and outcome data were collected from medical records.
Results The application of the 2021 molecular markers shows Kaplan-Meier curves with a significant difference between the groups for all survival. Molecular classification under the 2021 guidelines revealed a total of 39 patients (39/594, 7%) with a change in risk group in relation to the 2016 classification system: the shift was alone due to either P53abn or POLEmut molecular marker. In order to ensure correct 2021 molecular risk classification, not all patients with endometrial cancer need a molecular diagnostic: 386 (65.0%) cases would need to be analyzed by TP53 IHC, only 44 (7.4%) by MMR IHC and 109 (18.4%) POLE sequencing reactions.
Conclusion Application of the 2021 molecular risk groups is feasible and shows significant differences in survival. IHC for TP53 and MMR and applying POLE sequencing is only needed in selected cases and leads to shifting risk groups both upward and downward for a sizeable number of patients.
- endometrial cancer
- genomic subgroups
- risk group
- MMR
- POLE
- P53
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding sources are: Bernese Cancer League (https://bern.krebsliga.ch/), Swiss National Science Foundation (IZSE70_177073)http://www.snf.ch/; Avtal om Lakarutbildning och Forskning (ALF), Stockholm County (grant no 550411), Cancer research funding from 'Radiumhemmet' Stockholm, Sweden (grant no 154112) https://www.rahfo.se, Magnus Bergvalls Stiftelse, Cancerfonden, and Foundation for clinical-experimental cancer research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local ethics boards in Stockholm and in Bern (2016/362 and 2018-00479, respectively)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to ethical constraints, the individual level cohort data cannot be made publicly available.
Abbreviations
- EC
- endometrial cancer
- LVSI
- lymphovascular space invasion
- POLE
- polymerase epsilon
- TGCA
- The Cancer Genome Atlas
- TMA
- tissue microarray
- OS
- overall survival
- DSS
- disease-specific survival
- RFS
- recurrence-free survival
- IHC
- Immunohistochemistry
- ESGO
- European Society of Gynecological Oncology
- ESTRO
- European Society for Radiotherapy and Oncology
- ESP
- European Society of Pathology